Nectar Lifesciences, the fast-growing manufacture of generic pharmaceutical active pharmaceutical ingredients (APIs) and formulation products has touched yet another significant milestone by receiving European cGMP (current good manufacturing practices) approval for its Cephalosporin APIs' manufacturing facility in Dera Bassi, Punjab.

NecLife has received the European cGMP compliance certification through successful inspection by the Portugal Authority - National Authority of Medicines and Health Products, INFARMED.

This approval is valid for three years for calendar years 2015 to 2017. The INFARMED certificate is accepted by all EU Health Authorities and by authorities of several other countries.

Shares of the company gained Rs 4.4, or 12.57%, to trade at Rs 39.40. The total volume of shares traded was 1,400,444 at the BSE (2.08 p.m., Tuesday).